BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vollrath I, Mathaes R, Sediq AS, Jere D, Jörg S, Huwyler J, Mahler H. Subvisible Particulate Contamination in Cell Therapy Products—Can We Distinguish? Journal of Pharmaceutical Sciences 2020;109:216-9. [DOI: 10.1016/j.xphs.2019.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Hu A, Chen H, Liang J, Liu C, Li F, Mu C. Cell-based therapeutics for the treatment of hematologic diseases inside the bone marrow. J Control Release 2021;339:1-13. [PMID: 34536449 DOI: 10.1016/j.jconrel.2021.09.018] [Reference Citation Analysis]
2 Scott M, Clarke D, Lipsitz Y, Brandwein H, Allickson J, Alzebdeh D, Aleksic S, Kraft C, Lhu L, Cornetta K. Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies. Cytotherapy 2020;22:669-76. [PMID: 32713719 DOI: 10.1016/j.jcyt.2020.06.011] [Reference Citation Analysis]
3 Jere D, Sediq AS, Huwyler J, Vollrath I, Kardorff M, Mahler HC. Challenges for Cell-Based Medicinal Products From a Pharmaceutical Product Perspective. J Pharm Sci 2021;110:1900-8. [PMID: 33307042 DOI: 10.1016/j.xphs.2020.11.040] [Reference Citation Analysis]